Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California. more
Time Frame | ANRO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.67% | -0.94% | -2.6% |
1-Month Return | -9.5% | -5.08% | -1.08% |
3-Month Return | -69.9% | -10.62% | 3.45% |
6-Month Return | -61.76% | -6.18% | 8.57% |
1-Year Return | -75% | 1.98% | 24.3% |
Sep '21 | Sep '22 | Sep '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | 210.00K | - | - | [{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] | ||
Cost of Revenue | 145.00K | 342.00K | 373.00K | [{"date":"2021-09-30","value":38.87,"profit":true},{"date":"2022-09-30","value":91.69,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] | ||
Gross Profit | 65.00K | (342.00K) | (373.00K) | [{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-526.15,"profit":false},{"date":"2023-09-30","value":-573.85,"profit":false}] | ||
Gross Margin | 30.95% | - | - | [{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] | ||
Operating Expenses | 12.12M | 28.85M | 37.81M | [{"date":"2021-09-30","value":32.06,"profit":true},{"date":"2022-09-30","value":76.3,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] | ||
Operating Income | (12.06M) | (29.19M) | (37.81M) | [{"date":"2021-09-30","value":-1205600000,"profit":false},{"date":"2022-09-30","value":-2919200000,"profit":false},{"date":"2023-09-30","value":-3780900000,"profit":false}] | ||
Total Non-Operating Income/Expense | 2.87M | 1.60M | 2.48M | [{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":55.59,"profit":true},{"date":"2023-09-30","value":86.49,"profit":true}] | ||
Pre-Tax Income | (9.19M) | (27.71M) | (36.30M) | [{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false}] | ||
Income Taxes | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] | ||
Income After Taxes | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] | ||
Income From Continuous Operations | (9.19M) | (27.71M) | (36.30M) | [{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] | ||
Net Income | (9.19M) | (27.71M) | (36.30M) | [{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false}] | ||
EPS (Diluted) | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
ANRO | |
---|---|
Cash Ratio | 12.96 |
Current Ratio | 13.09 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ANRO | |
---|---|
ROA (LTM) | -32.36% |
ROE (LTM) | -56.72% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ANRO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ANRO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.64 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Alto Neuroscience, Inc. (ANRO) share price today is $4
Yes, Indians can buy shares of Alto Neuroscience, Inc. (ANRO) on Vested. To buy Alto Neuroscience, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Alto Neuroscience, Inc. (ANRO) via the Vested app. You can start investing in Alto Neuroscience, Inc. (ANRO) with a minimum investment of $1.
You can invest in shares of Alto Neuroscience, Inc. (ANRO) via Vested in three simple steps:
The 52-week high price of Alto Neuroscience, Inc. (ANRO) is $24. The 52-week low price of Alto Neuroscience, Inc. (ANRO) is $3.56.
The price-to-earnings (P/E) ratio of Alto Neuroscience, Inc. (ANRO) is
The price-to-book (P/B) ratio of Alto Neuroscience, Inc. (ANRO) is 0.64
The dividend yield of Alto Neuroscience, Inc. (ANRO) is 0.00%
The market capitalization of Alto Neuroscience, Inc. (ANRO) is $104.91M
The stock symbol (or ticker) of Alto Neuroscience, Inc. is ANRO